Eupraxia Pharmaceuticals Inc.
EPRXF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $210 | $193 | $112 | $117 |
| Gross Profit | -$210 | -$193 | -$112 | -$117 |
| % Margin | – | – | – | – |
| R&D Expenses | $27,887 | $17,203 | $9,679 | $860 |
| G&A Expenses | $0 | $5,808 | $8,887 | $1,270 |
| SG&A Expenses | $9,792 | $5,808 | $8,887 | $1,270 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $37,679 | $23,204 | $18,678 | $2,246 |
| Operating Income | -$37,889 | -$22,635 | -$20,872 | -$2,246 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$290 | -$341 | -$4,903 | -$1,765 |
| Pre-Tax Income | -$38,179 | -$23,917 | -$23,370 | -$4,011 |
| Tax Expense | -$90 | $931 | -$1,344 | $1,868 |
| Net Income | -$38,089 | -$23,259 | -$22,990 | -$3,997 |
| % Margin | – | – | – | – |
| EPS | -1.58 | -1.21 | -1.61 | -0.31 |
| % Growth | -30.6% | 24.8% | -419.4% | – |
| EPS Diluted | -1.58 | -1.21 | -1.61 | -0.31 |
| Weighted Avg Shares Out | 24,147 | 19,285 | 14,243 | 12,865 |
| Weighted Avg Shares Out Dil | 24,147 | 19,285 | 14,243 | 12,865 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,165 | $569 | $66 | $0 |
| Interest Expense | $1,579 | $1,588 | $1,297 | $1,882 |
| Depreciation & Amortization | $210 | $193 | $112 | $117 |
| EBITDA | -$37,395 | -$22,441 | -$20,761 | -$1,789 |
| % Margin | – | – | – | – |